Ikeuchi Takeshi
Department of Molecular Genetics, Brain Research Institute, Niigata University.
Brain Nerve. 2019 Oct;71(10):1081-1088. doi: 10.11477/mf.1416201407.
During the past 20 years, genome studies for Alzheimer's disease (AD) have elucidated the pathogenesis of AD including the amyloid hypothesis. However, clinical trials of the disease modifying drugs for AD developed based on the amyloid hypothesis have been largely unsuccessful. New genes associated with AD have been identified through comprehensive genome analyses such as genome-wide association studies and whole genome/exome sequencing using next-generation sequencers. With these efforts, new therapeutic targets to AD have been explored. This review summarizes the genetic make-up of AD in terms of both risk and protective factors from the viewpoint of novel therapeutic targets to AD.
在过去20年里,针对阿尔茨海默病(AD)的基因组研究阐明了AD的发病机制,包括淀粉样蛋白假说。然而,基于淀粉样蛋白假说开发的AD疾病修饰药物的临床试验大多未取得成功。通过全基因组关联研究和使用下一代测序仪进行的全基因组/外显子组测序等全面基因组分析,已经鉴定出与AD相关的新基因。通过这些努力,探索了AD的新治疗靶点。本综述从AD新治疗靶点的角度,总结了AD在风险和保护因素方面的基因构成。